A next-generation liquid biopsy platform simultaneously analyzing circulating tumor DNA (ctDNA), protein biomarkers, and DNA methylation signatures detected 12 different cancer types from a single blood draw with 89% overall sensitivity and 99.4% specificity in a prospective validation cohort of 14,000 individuals, marking a significant advance in multi-cancer early detection.

The Multi-Cancer Early Detection Challenge

Cancer is most treatable when caught early, yet most cancers lack approved screening tests. Of the 12 cancer types with the highest mortality burden — including ovarian, pancreatic, gastric, and esophageal cancers — fewer than half have screening recommendations for average-risk individuals. A single blood test capable of detecting multiple cancer types simultaneously could transform oncology by enabling screening for cancers currently diagnosed only at symptomatic, late stages.

The OmniScan Platform

OmniScan analyzes three analyte types in a single 10 mL blood draw: fragment patterns and sequence characteristics of circulating tumor DNA, a panel of 52 cancer-associated protein biomarkers, and genome-wide CpG methylation signatures from cell-free DNA. A machine learning classifier integrates signals across all three analyte types to generate a cancer probability score and, when cancer is detected, a tissue-of-origin prediction.

Validation Study Results

The ASCEND validation study enrolled 4,500 patients with newly diagnosed cancer across 12 cancer types and 9,500 cancer-free controls at 68 sites. OmniScan achieved 89% overall sensitivity, with sensitivity varying by stage: 62% for Stage I, 81% for Stage II, 93% for Stage III, and 97% for Stage IV.

Tissue-of-origin was correctly identified in 91% of true-positive cases — a critical capability allowing appropriate diagnostic workup to be directed efficiently. Specificity was 99.4%, corresponding to fewer than one false positive per 167 screened individuals.

Cancer-Type Performance

Performance varied across cancer types. Sensitivity exceeded 90% for colorectal, ovarian, and lung cancers. Pancreatic cancer detection achieved 76% sensitivity — still remarkable given that this cancer is notoriously difficult to detect early and carries a 5-year survival rate of only 12% at current presentation stages. Breast cancer sensitivity was 71%, somewhat lower than mammography but offering the advantage of detecting other cancers simultaneously.

FDA Pathway

OmniScan has received Breakthrough Device designation. The FDA has indicated it will consider approval based on demonstrated early detection capability paired with evidence from ongoing randomized trials showing mortality reduction — the PREDICT trial, enrolling 200,000 individuals across 10 years, is designed to provide this evidence but results are not expected until 2034.

A compassionate access program is available for high-risk individuals while full approval is sought.

⚕️ Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.